^
    DRUG:

    Herceptin (trastuzumab)

    i
    Other names: R 597, R597, RG597




    Show legend
    Group by Gene:
    Include preclinical:

    Biliary Tract Cancer
    Bladder Cancer
    Breast Cancer
    Cervical Cancer
    Childhood B Acute Lymphoblastic Leukemia
    Cholangiocarcinoma
    Colon Cancer
    Colorectal Cancer
    Endometrial Adenocarcinoma
    Endometrial Cancer
    Esophageal Adenocarcinoma
    Esophageal Cancer
    Esophageal Squamous Cell Carcinoma
    Estrogen Receptor Positive Breast Cancer
    Gallbladder Cancer
    Gastric Adenocarcinoma
    Gastric Cancer
    Gastroesophageal Cancer
    Gastroesophageal Junction Adenocarcinoma
    HER2 Negative Breast Cancer
    HER2 Positive Breast Cancer
    Hormone Receptor Negative Breast Cancer
    Hormone Receptor Positive Breast Cancer
    Lung Adenocarcinoma
    Lung Cancer
    Melanoma
    Non Small Cell Lung Cancer
    Ovarian Cancer
    Pancreatic Adenocarcinoma
    Pancreatic Cancer
    Prostate Cancer
    Rectal Cancer
    Salivary Gland Cancer
    Small Cell Lung Cancer
    Solid Tumor
    Triple Negative Breast Cancer
    Urothelial Cancer
    Uterine Cancer
    HER-2 positive
    A1
    1. HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + pertuzumab [A1]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab [A1]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + tucatinib [A1]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + lapatinib [A2]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + abemaciclib [A2]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + pyrotinib [B]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + copanlisib [C2]HER-2 positive|HER2 Positive Breast Cancer|bevacizumab + trastuzumab [C2]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + atezolizumab + pertuzumab [C2]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + ruxolitinib [C3]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + tremelimumab [C3]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + LZM-005 [C3]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + MM-302 [C3]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + S-222611 [C3]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + rivoceranib [C3]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + atezolizumab [C3]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + everolimus [D]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + GS-4721 [D]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab [D]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + talazoparib [D]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + BMS-202 [D]HER-2 positive|HER2 Positive Breast Cancer|trastuzumab + ZN-c3 [D]
    HER-2 overexpression
    HER-2 amplification
    HER-2 expression
    HER-2 mutation
    HER-2 positive + HER-2 amplification
    HER-2 S310F
    HER-2 expression + HER-2 amplification
    HER-2 exon 20 insertion
    HER-2 A1170P
    HER-2 I655V
    HER-2 overexpression + HER-2 amplification
    HER-2 L755S
    HER-2 V777L
    HER-2 778insGSP
    HER-2 negative
    HER-2 mutation + HER-2 T798I
    HER-2 exon 19 deletion
    HER-2 L755P
    HER-2 S310F + HER-2 amplification
    HER-2 amplification + HER-2 mutation
    HER-2 L755_T759del
    HER-2 mutation + HER-2 positive
    HER-2 S310Y
    HER-2 expression + HER-2 L869R
    HER-2 V773L
    HER-2 C634R
    HER-2 L768S
    p95HER2 mutation
    HER-2 1899‐1G>A
    HER-2 underexpression
    HER-2 expression + HER-2 D769H
    HER-2 K753E
    HER-2 amplification + RAS wild-type + BRAF wild-type
    BRAF wild-type + HER-2 positive
    HR positive
    HR negative
    ER positive + PGR positive
    PIK3CA mutation
    PIK3CA G1049R
    PIK3CA Q546
    PIK3CA H1047
    PIK3CA E545
    PIK3CA E542K
    PIK3CA M1043I
    PIK3CA wild-type
    PIK3CA E545K
    PIK3CA H1047R
    PIK3CA mutation + HR negative
    ER positive
    ER negative
    HR positive + HER-2 positive
    HR positive + HER-2 amplification
    HER-2 amplification + ER positive + PGR negative
    HR positive + HER-2 mutation
    ERBB3 amplification
    ERBB3 mutation
    ERBB3 G284R
    ERBB3 amplification + ERBB3 mutation
    ABCB1 C1236T
    ABCB1 C3435T
    ABCB1 G2677T
    ABCB1 G1236T + ABCB1 G2677T
    ACTA2 elevation
    RAS wild-type + HER-2 positive
    MYBL2 overexpression
    PD-1 overexpression
    ADRB2 overexpression
    FCGR3A 158V
    PD-L1 expression
    HER-2 expression + TMB-H
    PD-L1 overexpression
    HER-2 overexpression + KRAS wild-type
    HER-2 amplification + KRAS wild-type
    TMB-H + HER-2 positive
    HER-2 amplification + KRAS exon 2 wild-type
    HER-2 amplification + KRAS G12D
    PD-L1 elevation
    ACTA2 overexpression
    KRAS mutation + HER-2 positive
    HER-2 positive + PD-L1 expression
    YAP1 overexpression
    PTEN expression
    HR-positive + PIK3CA wild-type
    FGFR1 amplification
    EGFR expression
    EGFR mutation
    PIK3CA mutation + HER-2 positive
    PIK3CA H1047R + HER-2 amplification
    PIK3CA mutation + HR positive
    PTEN deletion
    PTEN rs701848
    IL6 elevation
    NRG1 overexpression
    EGF overexpression
    PIK3R1 mutation + HER-2 positive
    PIK3C3 mutation + HER-2 positive
    ERBB4 mutation + HER-2 positive
    NF1 mutation + HER-2 positive
    AXL-L
    MCM10 overexpression
    CD8-H
    WBP2 overexpression
    KMT2B mutation
    KIR3DL2 mutation
    MUC16 mutation
    ERBB3 mutation + HER-2 amplification
    BARD1 T351T
    RAS wild-type + BRAF wild-type + HER-2 positive
    TNFA elevation
    IL18 elevation
    VHL mutation
    AKT2 expression
    MAF1 overexpression
    TGFBI promoter hypermethylation
    GRB7 positive
    POLE E790Q + ERBB2 amplification + TMB-H
    HER-2 amplification + MET amplification
    MSI-H/dMMR + TMB-H
    PIK3R1 EY451delinsD
    POLE mutation + PD-L1 negative + TMB-H
    IRF8 overexpression + ER negative
    miR-21 overexpression
    PGR positive
    MET overexpression + HER-2 overexpression
    MET expression + HER-2 expression
    Rbsig overexpression
    MAF1 expression
    NDUFA4L2 overexpression
    MLH1 mutation
    BCL6 overexpression
    SMARCB1 mutation
    SMO mutation
    CD36 overexpression
    HGF amplification
    miR-1246 overexpression
    STAT6 underexpression
    ATM mutation
    CEACAM6 positive + HER-2 positive
    SPP1 mutation
    miR‐223 overexpression
    LDH elevation
    SPP1 elevation
    MET amplification
    PPP2R2B underexpression
    AFAP1-AS1 overexpression
    miR-98-5p underexpression
    PTPN2 amplification
    MALAT1 overexpression
    STAT6 deletion + HER-2 overexpression
    KRAS mutation
    DLD overexpression
    NCAPG overexpression
    miR-155 overexpression
    IGF2 overexpression
    ERCC1 negative
    ERCC1 overexpression
    XRCC1 overexpression
    MUC4 expression
    TCEAL9 overexpression
    HER-2 positive + CAV1 overexpression
    MYC amplification
    CUL7 overexpression
    RAD21 amplification
    MYC amplification + HER-2 amplification
    miR-101-5p overexpression
    YES1 amplification
    ARPP19 overexpression
    CD44 expression
    MYC mutation
    TP53 mutation
    ERBB4 expression
    HER-2 positive + GATA6 amplification
    HER-2 positive + APC mutation
    HER-2 positive + MYC amplification
    HOTAIR overexpression
    HER-2 positive + TP53 mutation
    CDYL2 overexpression
    HER-2 amplification + AXL expression
    ANXA1 expression
    PIK3CA mutation + PTEN underexpression
    BIRC5 overexpression
    ZNF649-AS1 overexpression
    HER-2 overexpression + PTEN deletion
    IL21R overexpression